Lesson
Triage: Severe Pressure or Hypertensive Emergency
In nonpregnant adults, acute organ injury distinguishes hypertensive emergency from severe pressure alone. Pregnancy and postpartum severe hypertension require a separate, lower-threshold urgent pathway.
- Reliable repeat measurement
- Acute target-organ injury
- Selective diagnostic testing
- Severe asymptomatic hypertension
Treat the patient and a reliable signal
Find new or worsening injury
Pregnancy severe pressure needs urgent care even without other injury
Match urgency to the injured organ
Verify the signal while assessing the patient
Repeat pressure with the correct cuff and technique without delaying stabilization. Pain, agitation, urinary retention, hypoxemia, substances, withdrawal, medications, and measurement error can amplify a reading.
Search for acute organ injury
Use symptoms, examination, ECG, troponin, kidney and urine data, neurologic imaging, aortic imaging, fundus findings, and obstetric evaluation selectively. In nonpregnant adults, new injury rather than a historical diagnosis defines the emergency. In pregnancy or postpartum, do not wait for additional organ injury before treating persistent severe pressure.
Do not confuse severe pressure with emergency
The 2025 guideline directs nonpregnant patients above 180 over 120 without acute target-organ damage toward timely outpatient oral initiation, reinstitution, or intensification. Routine reactive intravenous or oral rescue in hospitalized patients without acute injury can cause harm.
Recognize the obstetric exception
Pregnancy or postpartum systolic pressure at least 160 or diastolic pressure at least 110 mm Hg, persistent for 15 minutes, requires urgent treatment. Do not wait for both numbers to rise, proteinuria, symptoms or abnormal laboratory results. Begin treatment as soon as possible within 30 to 60 minutes of confirmation under the obstetric pathway.
Escalate the setting when injury is present
A true emergency requires continuous or very frequent monitoring, a short-acting titratable agent, organ-specific diagnostics, and coordinated critical, neurologic, cardiac, vascular, renal, or obstetric care.
Quick check
Checking for saved practice…
Lesson
Autoregulation and Controlled Pressure Reduction
Chronically hypertensive tissue may depend on a higher perfusion pressure. Emergency treatment therefore uses a smooth partial reduction with explicit exceptions rather than immediate normalization.
- Shifted autoregulation
- Condition-specific targets
- Titrated intravenous agents
- Overshoot and variability
Abrupt normalization may cause ischemia
Avoid one universal target
Match the entire product to the organ state
Prevent variability, overshoot, and toxicity
Protect autoregulated perfusion
Chronic pressure shifts cerebral, coronary, and renal autoregulation. An abrupt fall can cross the lower limit and cause ischemia even when the resulting number looks normal for an outpatient.
Use the organ-specific target
Many emergencies use an initial controlled partial reduction, but acute aortic syndrome, ischemic stroke, intracerebral hemorrhage, pregnancy, and selected cardiac states have distinct targets and time courses.
Apply the general timeline only when it fits
For nonpregnant, nonstroke adults without a compelling condition, the 2025 guideline limits the first-hour systolic reduction to 25%. If stable, proceed below 160/100 mm Hg over the next 2 to 6 hours, then cautiously toward systolic 130 to 140 over the next 24 to 48 hours. Organ-specific exceptions take priority.
Do not transfer the obstetric nifedipine pathway
Immediate-release nifedipine is not a rescue treatment for rapid pressure reduction in nonpregnant adults. The capsule label reports profound hypotension, myocardial infarction and deaths with this use. ACOG supports immediate-release oral nifedipine within a monitored pregnancy or postpartum severe-hypertension protocol, particularly without IV access. That guideline-supported use is distinct from the product's labeled indication and from routine adult hypertension care.
Choose a predictable titratable medicine
Nicardipine, clevidipine, labetalol, esmolol, nitroglycerin, and other agents differ in vascular, cardiac, cerebral, pulmonary, renal, pregnancy, and toxicologic effects. Select the mechanism rather than treating them as interchangeable.
Match formulation and toxicity to the patient
Clevidipine is delivered in a lipid emulsion, so allergy, lipid-metabolism, caloric, handling, and line considerations matter. Nitroprusside can generate cyanide and thiocyanate, especially with greater exposure or impaired clearance. Fenoldopam can increase intraocular pressure and contains sulfite. These are selection and monitoring issues, not details to discover after the infusion starts.
Minimize variability
Continuous infusion and frequent pressure measurement permit small adjustments. Repeated long-acting or unpredictable boluses can cause oscillation, while pressure-source mismatch and arterial-line leveling errors can mislead titration.
Quick check
Checking for saved practice…
Lesson
Nicardipine and Clevidipine: Preparing and Titrating Infusions
Concentration, vascular access, titration, lipid exposure, and handling determine how these arterial vasodilators are delivered safely.
- Concentration and pump rate
- Infusion access
- Lipid exposure
- Product exclusions
The same mg/hour can require a different mL/hour
Follow the selected product's route and handling instructions
Monitor pressure and pulse during adjustment
Clevidipine adds lipid and calories
Match nicardipine rate to concentration
For patients not receiving oral nicardipine, the cited premix label starts at 5 mg/hour, increasing by 2.5 mg/hour every 5 to 15 minutes to a 15 mg/hour ceiling. After rapid titration achieves the goal, the label reduces the rate to 3 mg/hour. A 0.2 mg/mL bag needs half the pump rate of a 0.1 mg/mL bag for the same dose.
Protect the infusion route
This nicardipine premix needs no dilution and a separate line. Use central access or a large peripheral vein; change peripheral sites every 12 hours. Advanced aortic stenosis precludes use. Titrate cautiously with heart failure or liver or kidney impairment, monitoring pressure, pulse and the site.
Respond to intolerance and interactions
Stop nicardipine for unacceptable hypotension or tachycardia. Once pressure and pulse stabilize, the label permits restarting at 3 to 5 mg/hour with reassessment. Nicardipine can raise tacrolimus or cyclosporine exposure; arrange frequent trough monitoring and adjust the immunosuppressant with the treating team.
Titrate clevidipine with a slowing approach
Start at 1 to 2 mg/hour. The label permits initial doubling every 90 seconds; near goal, use smaller increases every 5 to 10 minutes. Most patients respond at 4 to 6 mg/hour. Experience at 32 mg/hour is limited. Track cumulative volume: the label recommends no more than 1,000 mL in 24 hours and notes little experience beyond 72 hours.
Monitor beyond the clevidipine infusion
Reduce the dose for hypotension or reflex tachycardia; the label advises against adding a beta blocker solely to treat clevidipine-induced tachycardia. Monitor heart failure carefully because negative inotropy can worsen it. Clevidipine does not prevent beta-blocker withdrawal. After prolonged infusion without transition to another antihypertensive, monitor for rebound for at least eight hours. Continue pressure and pulse monitoring until stable.
Account for clevidipine calories
At 0.5 mg/mL, an illustrative 4 mg/hour infusion delivers 8 mL/hour. If unchanged for 24 hours, that supplies 192 mL, about 384 kcal and 38.4 g lipid. Include this exposure in the nutrition plan; use actual administered volume when rates change.
Use the puncture time
Clevidipine is ready to use: do not dilute it or share its line with other medicines. Discard unused emulsion within 12 hours after stopper puncture, even if substantial volume remains. Aseptic handling and a documented puncture time are essential.
Screen product-specific exclusions
The clevidipine label contraindicates use with soy or egg allergy, defective lipid metabolism, or severe aortic stenosis. Do not transfer another lipid emulsion's allergy advice to this product.
Quick check
Checking for saved practice…
Lesson
Labetalol, Nitroprusside, Fenoldopam, and Enalaprilat
Delivery intervals, toxic metabolites, compensatory responses, and delayed drug effects create different monitoring needs.
- Injection timing
- Toxic metabolite accumulation
- Electrolyte monitoring
- ACE-inhibitor interactions
Two-minute administration is not a two-minute repeat schedule
Distinguish cyanide from thiocyanate toxicity
Assess compensatory responses and ocular risks
Review renal function, potassium, and ACE-inhibitor interactions
Separate injection duration from dose interval
The cited labetalol label starts at 0.25 mg/kg, capped at 20 mg, over two minutes. Its full dosing section permits subsequent 20 to 80 mg injections at ten-minute intervals, guided by response; safety above 300 mg is unestablished. Two minutes describes delivery, not automatic repeat dosing. Use the selected indication-specific protocol.
Distinguish the labetalol products
The cited 1 mg/mL premix starts at 2 mg/minute, equivalent to 120 mL/hour; adjust to monitored response. Do not add medicines or dilute the bag; discard the remainder 24 hours after starting. The 5 mg/mL vial or syringe is a different presentation. Verify concentration and units before programming.
Protect conduction and ambulation
Before IV labetalol, assess airway disease, bradycardia, heart block, shock and overt failure. The cited injection label contraindicates coadministration with nondihydropyridine calcium-channel antagonists such as verapamil; its interaction section does not restrict that warning to IV calcium-channel blockers. Monitor pressure and rhythm. Confirm upright tolerance before ambulation because postural hypotension can persist after IV dosing.
Limit nitroprusside exposure
The cited ready-to-use label starts at 0.3 mcg/kg/min with continuous pressure monitoring and at least five minutes of assessment before adjustment. Its maximum is 10 mcg/kg/min for the shortest possible duration. For eGFR below 30 mL/min/1.73 m2, keep the mean rate below 3 mcg/kg/min; in anuria, limit it to 1 mcg/kg/min.
Check nitroprusside exclusions
The cited label prohibits concomitant sildenafil, tadalafil, vardenafil, or riociguat. Review compensatory hypertension, inadequate cerebral circulation or moribund status (ASA class 5E) in emergency surgery, Leber optic atrophy or tobacco amblyopia, and acute heart failure with low peripheral resistance. A falling pressure does not establish that the drug is appropriate.
Separate the toxic metabolites
Hepatic dysfunction increases cyanide susceptibility; renal impairment promotes thiocyanate accumulation. Rising dose requirements can signal cyanide toxicity before acidosis appears. Stop nitroprusside and initiate urgent toxicology management when toxicity is suspected. Tinnitus, miosis and hyperreflexia suggest thiocyanate neurotoxicity; severe cases may require hemodialysis.
Name the cyanide antidote correctly
AHA recommends hydroxocobalamin for life-threatening cyanide poisoning. Cyanocobalamin is not a substitute. If hydroxocobalamin is unavailable, sodium nitrite plus sodium thiosulfate is the recommended alternative in this setting. These cyanide rescue measures do not replace management of thiocyanate accumulation. See the Toxicology and Antidotes module for dosing and preparation.
Prepare and titrate fenoldopam
Adult labeling starts at 0.01 to 0.3 mcg/kg/min, with increases of 0.05 to 0.1 mcg/kg/min at intervals of at least 15 minutes. The highest studied rate was 1.6 mcg/kg/min; adult maintenance is limited to 48 hours. Dilute the concentrate in normal saline or D5W before infusion.
Calculate fenoldopam delivery
The adult dilution table produces 40 mcg/mL. For an illustrative 80 kg adult prescribed 0.1 mcg/kg/min, the rate is 0.1 × 80 × 60 ÷ 40 = 12 mL/hour. Check micrograms versus milligrams. Discard diluted solution not yet being administered after four hours at room temperature or 24 hours refrigerated.
Monitor potassium and compensatory responses
Fenoldopam can lower potassium within hours and cause dose-related tachycardia. Monitor electrolytes, pressure and pulse. Avoid concurrent beta blockers: suppressing the compensatory sympathetic response can worsen hypotension. Review glaucoma, ocular hypertension and sulfite sensitivity before selection.
Recognize enalaprilat's delayed peak
IV enalaprilat is labeled for hypertension when oral treatment is impractical. Effects begin around 15 minutes but may peak one to four hours later and last about six hours. This time course limits rapid fine adjustment; do not treat an early reading as the final response.
Adjust enalaprilat for susceptibility
The usual labeled dose is 1.25 mg IV over five minutes every six hours. Start at 0.625 mg with diuretic therapy or creatinine clearance at or below 30 mL/min. Patients at high hypotension risk need no more than 0.625 mg initially, administered over at least five minutes, preferably longer, with close supervision.
Screen ACE-inhibitor risks
Avoid enalaprilat in pregnancy and with prior ACE-inhibitor angioedema, hereditary or idiopathic angioedema, or product hypersensitivity. Monitor potassium and kidney function; assess volume depletion and renal artery disease. Review interacting medicines before dosing.
Respect the sacubitril interval
An intravenous route does not bypass ACE-inhibitor interactions. Sacubitril/valsartan labeling prohibits concurrent ACE inhibition and requires at least 36 hours when switching in either direction. Verify the last administered dose before considering enalaprilat; choose another appropriate pathway when the interval has not elapsed.
Quick check
Checking for saved practice…
Lesson
Neurologic Hypertensive Emergencies
Ischemic stroke, intracerebral hemorrhage, encephalopathy, PRES, seizures, and other neurologic syndromes can share severe pressure but require different strategies.
- Ischemic stroke and reperfusion
- Intracerebral hemorrhage
- Hypertensive encephalopathy
- PRES and mimics
Do not infer stroke type from pressure
Follow treatment-specific thresholds
Avoid excessive reduction
Treat while excluding mimics
Protect ischemic penumbra
In acute ischemic stroke, correct hypotension and hypovolemia and identify the reperfusion plan before choosing a pressure target. A competing emergency such as aortic dissection or pulmonary edema can require treatment even when stroke alone would not.
Recognize the nonreperfusion pathway
Without thrombolysis, thrombectomy or another urgent indication, starting or restarting antihypertensives within the first 48 to 72 hours does not prevent death or dependency when pressure is below 220/120 mm Hg. At or above that threshold, benefit remains uncertain. This is not a reason to ignore aortic dissection, acute heart failure or another competing emergency.
Distinguish thrombolysis from thrombectomy
Before IV thrombolysis, lower systolic below 185 and diastolic below 110 mm Hg; afterward maintain below 180/105 for at least 24 hours. For thrombectomy without prior thrombolysis, the guideline considers at or below 185/110 reasonable before treatment, then at or below 180/105 during and for 24 hours afterward.
Do not equate lower with better after reperfusion
After IV thrombolysis in mild-to-moderate ischemic stroke, targeting systolic below 140 provides no functional benefit. After successful thrombectomy for anterior-circulation large-vessel occlusion (mTICI 2b, 2c or 3), targeting below 140 during the first 72 hours is harmful when no other condition requires a different target.
Use smooth control in selected ICH
For selected mild to moderate spontaneous intracerebral hemorrhage presenting with systolic 150 to 220, targeting about 140 and maintaining 130 to 150 may be reasonable. Lowering below 130 can be harmful, and severe hemorrhage requires individualized neurocritical management.
Start early while preserving smooth control
When acute pressure lowering is appropriate in spontaneous ICH, the guideline says starting within two hours of onset and reaching the target within one hour can be beneficial. Avoid sharp peaks and large fluctuations. These timing goals do not justify overshooting the selected target or delaying other hemorrhage care.
Respect the limits of the ICH evidence
The safety and efficacy of intensive lowering are not well established for large or severe hemorrhage or patients needing surgical decompression. The 140 target and 130 to 150 maintenance range belong to the specified mild-to-moderate group presenting at 150 to 220 mm Hg. More severe presentations require neurocritical assessment of perfusion and intracranial pressure.
Recognize encephalopathy
Headache, altered cognition, seizures, and visual symptoms with severe pressure can reflect failed cerebral autoregulation. Treat pressure while excluding hemorrhage, ischemia, toxic-metabolic disease, and other seizure causes. Urgent brain imaging and serial neurologic assessment help distinguish these diagnoses; a high reading alone does not establish hypertensive encephalopathy.
Treat PRES as a syndrome with causes
PRES is associated with severe pressure, pregnancy, kidney disease, autoimmune illness, and selected immunosuppressive or cytotoxic drugs. Control pressure, seizures, and the precipitant, while recognizing that hemorrhage or infarction can occur.
Do not overread the name PRES
Marked hypertension is not required, and edema can extend beyond posterior regions. Interpret MRI alongside symptoms, kidney disease, pregnancy, infection, and medication exposure. Observational series establish this variable presentation; they do not supply a universal pressure target or guarantee recovery.
Quick check
Checking for saved practice…
Lesson
Aortic, Coronary, and Pulmonary Emergencies
The aorta requires anti-impulse therapy, coronary ischemia requires demand-perfusion balance, and hypertensive pulmonary edema requires rapid afterload reduction and respiratory support.
- Acute aortic syndrome
- Acute coronary syndrome
- Hypertensive pulmonary edema
- Mechanism-specific vasodilators
Reduce heart rate and wall stress
Avoid reflex tachycardia and low diastolic pressure
Use vasodilation and respiratory support
No single infusion fits every syndrome
Use anti-impulse therapy for the aorta
Acute aortic syndrome threatens propagation and rupture. Rapid beta blockade, when not contraindicated, reduces heart rate and ejection force. Add vasodilation only after adequate anti-impulse control if pressure remains above target.
Specify the aortic targets
Use ICU care with arterial pressure monitoring. The aortic guideline targets heart rate 60 to 80 beats/min and systolic pressure below 120 mm Hg, or the lowest pressure that preserves organ perfusion. Treat pain concurrently. Suspected type A dissection requires emergency surgical evaluation; an improved pressure does not resolve the structural emergency.
Provide an alternative for rate control
When beta blockers are contraindicated or intolerable, an IV nondihydropyridine calcium-channel blocker may provide initial rate control if appropriate for cardiac function and conduction. Nicardipine does not serve this role. Add a vasodilator after rate control when pressure remains excessive.
Keep esmolol regimens indication specific
For gradual perioperative control, the label uses 500 mcg/kg over one minute, then 50 mcg/kg/min for four minutes before reassessment. Tachycardia dosing should not exceed 200 mcg/kg/min; perioperative hypertension may require up to 300. Aortic treatment follows its own monitored protocol, not an automatic transfer of the perioperative regimen.
Screen before esmolol
Label exclusions include severe bradycardia, block beyond first degree, sick sinus syndrome, decompensated failure, cardiogenic shock, pulmonary hypertension and hypersensitivity. Do not give it near IV cardiodepressant calcium-channel blockers such as verapamil while their cardiac effects persist. Monitor rhythm and pressure; reduce or stop for severe bradycardia or unacceptable hypotension.
Monitor glucose even without tachycardia
Esmolol can mask hypoglycemic tachycardia and increase severe or prolonged hypoglycemia risk, particularly with diabetes, childhood or fasting. Check glucose when symptoms or circumstances warrant; a controlled pulse does not exclude hypoglycemia.
Balance myocardial oxygen supply and demand
In acute coronary syndrome, reduce excessive afterload and sympathetic demand while preserving diastolic coronary perfusion. ECG, troponin, ventricular function, heart rate, and contraindications determine the drug.
Keep the coronary pathway moving
Obtain and interpret an ECG promptly, with a goal of ten minutes, and measure troponin. Persistent symptoms after a nondiagnostic ECG require serial ECGs. When the ECG establishes STEMI, do not delay reperfusion for biomarker results.
Reduce afterload in hypertensive pulmonary edema
Severe afterload can abruptly elevate left-sided filling pressure and flood the lungs. Noninvasive ventilation and titratable vasodilation can improve physiology quickly, while loop diuresis is used when congestion and renal response support it.
Match respiratory support to respiratory failure
The 2026 ESC HF guidance recommends oxygen for SpO2 below 90% or PaO2 below 60 mm Hg. Consider early noninvasive positive-pressure ventilation for respiratory distress with a rate above 25 breaths/min and SpO2 below 90%. Persistent, progressive respiratory failure despite oxygen or noninvasive support requires intubation. Track oxygenation and work of breathing alongside pressure.
Monitor perfusion during positive-pressure support
Positive intrathoracic pressure reduces venous return and ventricular filling. Monitor blood pressure and perfusion during noninvasive ventilation; reduced preload reserve, hypotension and right ventricular dysfunction require particular caution. Respiratory improvement does not rule out a fall in cardiac output.
Treat congestion and reassess perfusion
Hospitalized HF with significant fluid overload needs prompt IV loop diuresis. Without systemic hypotension, IV nitroglycerin or nitroprusside may be considered for dyspnea alongside diuretics. Follow congestion, perfusion and the precipitant; a lower cuff reading alone does not establish recovery.
Verify nitroglycerin preparation and tubing
The cited 5 mg/mL concentrate requires dilution in D5W or normal saline; never inject it directly. Use compatible low-absorbing tubing and an infusion pump. PVC and some filters remove drug unpredictably, so a dose established with one delivery system cannot simply be transferred to another.
Titrate the delivered nitrate dose
With nonabsorbing tubing, this label starts at 5 mcg/min, increasing by 5 mcg/min every three to five minutes initially. Once a response appears, make smaller adjustments farther apart. Continuously monitor pressure and heart rate, preserving systemic and coronary perfusion; use the condition-specific protocol.
Distinguish ACS guidance from the infusion label
The 2025 ACS guideline suggests an IV starting rate of 10 mcg/min, titrated to symptoms and hemodynamic tolerance. The product label discussed above starts at 5 mcg/min with nonabsorbing tubing. Identify the indication, preparation and monitored protocol; these are source-specific regimens, not a single universal starting dose.
Screen for nitrate exclusions in ACS
Avoid nitrates when right ventricular infarction is suspected, systolic pressure is below 90 mm Hg, or systolic pressure has fallen more than 30 mm Hg from baseline. Ask which PDE5 inhibitor was taken and when: avoid nitrates within 12 hours of avanafil, 24 hours of sildenafil or vardenafil, and 48 hours of tadalafil. Passing a time window does not override other contraindications.
Check dependence on venous return
Nitroglycerin reduces preload through venodilation. Its IV label contraindicates use in pericardial tamponade, restrictive cardiomyopathy and constrictive pericarditis, where reducing venous return can compromise output. A high pressure reading does not remove these exclusions.
Respect vasodilator contraindications
Nitroglycerin can fit ischemia and pulmonary edema, but do not combine it with riociguat: the riociguat label contraindicates nitrates and nitric oxide donors in any form because of hypotension. Riociguat is a soluble guanylate cyclase stimulator, not a PDE5 inhibitor; do not borrow PDE5 timing rules for it. Nitroprusside requires toxic-metabolite and organ-function awareness. Hydralazine has less predictable effects and specific rather than universal roles.
Quick check
Checking for saved practice…
Lesson
Pregnancy, Catecholamine Crisis, and Kidney Injury
Pregnancy and postpartum disease, catecholamine excess, substance toxicity, and acute kidney injury change thresholds, treatment order, monitoring, and the responsible team.
- Severe pregnancy hypertension
- Eclampsia prevention
- Alpha before beta in pheochromocytoma
- Renal target-organ injury
Use obstetric protocol and seizure prevention when indicated
Avoid unopposed vasoconstriction
Do not confuse chronic disease with acute damage
Agitation, temperature, and ischemia matter
Treat persistent severe pregnancy pressure urgently
Persistent systolic at least 160 or diastolic at least 110 in pregnancy or postpartum requires urgent obstetric treatment, even without additional symptoms or laboratory abnormalities. Protocol options include intravenous labetalol, intravenous hydralazine, or immediate-release oral nifedipine, selected by contraindications and access.
Keep obstetric reassessment intervals distinct
CO767's sample pathways reassess after ten minutes for IV labetalol and twenty minutes for IV hydralazine or immediate-release oral nifedipine. Further doses depend on persistent severe pressure. Failure despite appropriate successive treatment requires emergency specialist escalation. See Hypertension, Preeclampsia, and Eclampsia in Pregnancy and Lactation Pharmacotherapy for the dosing sequences.
Separate seizure prevention from pressure control
Magnesium sulfate prevents or treats eclamptic seizures but is not the primary antihypertensive. Monitor reflexes, respiration, urine output, and kidney function, and treat severe pressure simultaneously.
Act on magnesium toxicity
Loss of reflexes with respiratory depression requires stopping magnesium, urgent assistance and ventilatory support as needed. Injectable calcium must be available for rescue. Renal impairment raises accumulation risk; follow urine output, renal function, magnesium and clinical findings. A reassuring pressure reading does not exclude toxicity.
Resolve renal eligibility before magnesium dosing
ACOG lists moderate-to-severe renal failure as a magnesium contraindication. The cited product label instead provides a reduced regimen for severe renal impairment. That dosing schedule does not establish obstetric eligibility: obtain an urgent specialist plan. Milder impairment or oliguria can require lower maintenance dosing and serum monitoring; the pregnancy module details ACOG's approach.
Control alpha vasoconstriction before beta
In pheochromocytoma crisis, control alpha-mediated vasoconstriction before adding beta blockade when needed. Do not automatically transfer that sequence to acute cocaine poisoning: AHA 2025 considers vasodilators reasonable for cocaine-induced coronary vasospasm or hypertensive emergency and does not recommend beta blockers in that setting. Treat agitation and hyperthermia concurrently.
Use the crisis-specific adrenergic pathway
For pheochromocytoma or paraganglioma crisis, the 2025 Japan Endocrine Society guideline describes hospitalized treatment with IV phentolamine followed by infusion, then oral alpha blockade after the acute phase. Assess cardiac injury, rhythm, volume and organ perfusion concurrently. This crisis pathway is distinct from the label’s perioperative dosing and from treatment of stimulant poisoning.
Check phentolamine exclusions
The injection label contraindicates phentolamine with myocardial infarction or its history, angina, coronary insufficiency or other evidence suggesting coronary artery disease, and hypersensitivity. Marked hypotension, tachycardia and arrhythmias require close monitoring. A catecholamine-driven presentation does not remove these product-specific risks.
Separate phentolamine indications
The label's adult perioperative pheochromocytoma dose is 5 mg, with route and timing determined by the surgical setting. Reconstituted solution is used immediately. Norepinephrine extravasation uses local infiltration, not the same systemic regimen. The historical diagnostic blocking test is not the preferred screening approach; do not turn it into an emergency treatment protocol.
Interpret acute kidney injury in context
Kidney injury may be the target, the cause, or a consequence of excessive reduction. Compare baseline function, urine, electrolytes, hemolysis, volume, nephrotoxins, and perfusion rather than reacting to creatinine in isolation.
Quick check
Checking for saved practice…
Lesson
Monitoring, Oral Transition, and Recurrence Prevention
Safe resolution requires stable organ injury, smooth pressure, drug-specific oral transition, cause reconciliation, medication access, home monitoring, and a closed-loop handoff.
- Pressure variability
- Organ response
- Intravenous-to-oral timing
- Discharge and follow-up
Confirm the organ trajectory
Overlap when pharmacology requires it
Prevent recurrence
Make follow-up executable
Monitor the organ, not only the cuff
Serial neurologic examination, ECG and ischemia data, oxygenation, aortic findings, kidney and urine trends, pregnancy assessment, imaging, symptoms, and pressure variability determine whether treatment is helping.
Transition pharmacokinetically
Choose oral agents that fit the cause and comorbidity, and coordinate their onset with the infusion offset. Overlap is product specific: the cited nicardipine label starts oral nicardipine one hour before stopping IV therapy, but other oral agents at discontinuation. Follow the selected protocol and monitor the response.
Reconstruct why the emergency occurred
Review prior treatment, missed exposure, cost, side effects, substances, pressure-raising medicines, secondary causes, pregnancy, follow-up gaps, and health-system barriers. Stabilization without cause repair invites recurrence.
Close the loop
Document the organ diagnosis, pressure course, targets, current medicines, laboratory plan, pending tests, warning signs, home-monitoring technique, follow-up date, and responsible team. Confirm that medicines and equipment can actually be obtained.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 117 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- Japan Endocrine Society. 2025 PPGL guideline: sections I-4 and I-6
- ACOG Practice Bulletin 222: magnesium eligibility and renal monitoring
- ESC. 2026 heart failure guideline: oxygen and ventilatory support
- ESC. 2021 heart failure guideline, section 11.3.2: ventilation physiology
- Bayer. Adempas: nitrate contraindication, sections 4.2 and 7.1
- NCI PDQ. Pheochromocytoma: preoperative adrenergic blockade
- KDIGO. Published AKI guideline (2012), section2.3: evaluation and monitoring
- Hospira. Magnesium sulfate in dextrose: toxicity and renal monitoring (June2026)
- ACC/AHA. 2025 acute coronary syndromes guideline: initial assessment
- AHA/ACC/HFSA. 2022 heart failure guideline: hospitalized decompensation
- BIHS. Hypertensive crisis position document: encephalopathy diagnosis
- Fugate et al. PRES clinical and imaging cohort (2010)
- DailyMed. Enalaprilat: time course, dosing and precautions
- Novartis. Entresto: ACE-inhibitor switching contraindication
- Hikma. Phentolamine injection: indications, exclusions and preparation
- Baxter. Brevibloc prescribing information: dosing and updated hypoglycemia warning
- Baxter. Nitroglycerin in dextrose: mechanism and contraindications
- DailyMed. Nitroglycerin concentrate: dilution, tubing and titration
- Pfizer. Procardia capsules: acute pressure-reduction warning
- Pfizer. Corlopam prescribing information: preparation, dosing and precautions
- DailyMed. Ready-to-use sodium nitroprusside: dosing and toxic metabolites
- DailyMed. Nicardipine premix: concentration and transition instructions (June2025)
- DailyMed. Labetalol injection: dosing and safeguards (label revised September2024)
- AHA. 2026 correction to hypertension guideline: labetalol interval
- AHA/ACC. 2025 hypertension guideline, section6.2
- DailyMed. Cleviprex: administration, lipid exposure and contraindications
- ACOG Committee Opinion767: acute severe pregnancy and postpartum hypertension
- AHA. 2025 Special Circumstances of Resuscitation: Cocaine and Cyanide Poisoning
- AHA and ACC. 2025 High Blood Pressure Guideline
- American Heart Association. Elevated Blood Pressure in Acute Care
- AHA and ASA. 2026 Acute Ischemic Stroke Guideline
- AHA and ASA. 2022 Spontaneous Intracerebral Hemorrhage Guideline
- ACC and AHA. 2022 Aortic Disease Guideline
- ACOG. Severe Hypertension in Pregnancy Resources